Having trouble accessing articles? Reset your cache.

Gilead signals ‘urgency’ for M&A, working ‘night and day’ on coronavirus response

To execute on its plan to launch 10 transformative medicines in 10 years, Gilead will make M&A a priority in bolstering its pipeline, CEO Daniel O’Day said on the company’s earnings call Tuesday. The company is also investing in manufacturing for its antiviral remdesivir in response to the 2019-nCoV outbreak.

Gilead Sciences Inc. (NASDAQ:GILD) will invest in external pipeline opportunities, including “transformative partnerships” like

Read the full 636 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers